Roche’s multi-drug combination ‘improves overall survival of lung cancer’

Roche's new multi-drug therapy has improved overall survival levels for patients with advanced non-squamous non-small cell lung cancer (NSCLC), the company has said. 

Outlining the results of its Phase III, IMpower150 study, Roche said that using a combination of Tecentriq and Avastin, alongside carboplatin and paclitaxel, enabled patients to survive "significantly longer" than those just using Avastin with carboplatin and paclitaxel.

While the specific figures were not revealed by the firm, the study adds to the evidence that the inclusion of Tecentriq improves survival rates, with previous research indicating that the chances of the disease getting worse or causing death were reduced by 38 per cent. 

At the same time, other trials showed Tecentriq did not improve patient outcomes when not used in combination with Avastin.

Discussing the role Tecentriq could play in treatment, Roche’s Chief Medical Officer Sandra Horning said: “These results add to the growing body of evidence supporting the role of combining Tecentriq with Avastin. 

"We will submit these additional data to global health authorities and hope to bring this potential treatment option to patients as soon as possible.”

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.